Can Pralsetinib be used in combination with other targeted drugs?

Pralsetinib is a selective RET kinase inhibitor mainly used to treat non-small cell lung cancer and other related cancers carrying RET gene fusions or mutations. Regarding whether platinib can be used in combination with other targeted drugs, current clinical research and practical applications are still relatively cautious, mainly based on safety and drug interaction considerations.

First of all, as a targeted therapy drug, the single-agent efficacy of platinib has been clearly recognized in relevant indications. Since the mechanism of action of targeted drugs is highly specific, the combined use of other targeted drugs may bring about the advantages of superimposed drug effects, but it also increases the risk of drug-drug interactions and toxic side effects. Therefore, it is generally not recommended to use platinib in combination with other targeted drugs without sufficient clinical evidence to support it.

Secondly, if combined medication is considered, it must be done under the strict guidance of professional oncologists, and an appropriate combination should be selected based on the patient's specific condition, type of genetic mutation, and drug resistance mechanism. Some clinical trials are currently exploring the combined effect of platinib and immunotherapy or chemotherapy drugs, which may provide more basis for combined use in the future, but the combination of targeted drugs still needs to be carefully evaluated.

Finally, patient safety needs to be closely monitored during combined use and attention should be paid to potential drug interactions and adverse reactions. In particular, monitoring of liver function, hematological indicators and electrocardiogram cannot be ignored. In short, the application of platinib in combination with other targeted drugs is still in the exploratory stage. Patients should follow the doctor's instructions and do not adjust or combine drugs on their own to ensure that the treatment is safe and effective.

Reference materials:https://gavreto.com/